Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/140047/1/onco1230.pd

Lao, Christopher D.

Postow, Michael

Schadendorf, Dirk

Weber, Jeffrey S.

The Oncologist

English

PubMed

Deep Blue Documents

Management of Adverse Events Following Treatment With Anti‐Programmed Death‐1 Agents

Abstract
               Immune checkpoint inhibitors have emerged as a mainstay of melanoma therapy and are playing an increasingly important role in the treatment of other tumor types. The clinical benefit afforded by these treatments can be accompanied by a unique spectrum of adverse events, called immune-related adverse events (irAEs), which reflect the drug’s immune-based mechanism of action. IrAEs typically originate in the skin, gastrointestinal tract, liver, and endocrine system, although other organ systems may also be affected. This article provides an overview of irAEs associated with anti-programmed death-1 (anti-PD-1) antibodies (nivolumab and pembrolizumab) as monotherapy or in combination with anti-cytotoxic T-lymphocyte antigen-4 inhibition (ipilimumab), followed by a discussion of irAEs of special clinical interest based on the potential for morbidity, frequent steroid use, and inpatient admission. We review clinical trial data and provide recommendations on how to manage irAEs associated with anti-PD-1 agents based on clinical experience and established management guidelines. We further illustrate the practical considerations of managing irAEs by presenting three cases of immune-related toxicity in melanoma patients treated with nivolumab or pembrolizumab. A better understanding of the identification and management of irAEs will help inform health care providers about the risks associated with anti-PD-1 treatment, to ensure the safe and appropriate use of these important new treatments.</jats:p

Jeffrey S. Weber

Michael Postow

Christopher D. Lao

Dirk Schadendorf

Crossref

Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents

http://deepblue.lib.umich.edu/bitstream/2027.42/140047/1/onco1230.pdf

Management of Adverse Events Following Treatment With Anti‐Programmed Death‐1 Agents

Abstract

Similar works

Full text

Available Versions

Deep Blue Documents

Crossref